4'-epidoxorubicin versus mitomycin C intravesical chemoprophylaxis of superficial bladder cancer.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 1606981.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The authors report the preliminary data concerning a phase III study comparing the chemoprophylactic effects of mitomycin C and epirubicin in Ta-T1 primary and recurrent superficial bladder tumors. 60 patients were treated, 32 with epirubicin and 28 with mitomycin C, with a medium follow-up of 17.7 and 16.2 months, respectively. There were no systemic side effects. The remission rate was 62.5% in the epirubicin group and 64.2% in the mitomycin C group. Both drugs were equally useful in the chemoprophylaxis of superficial bladder cancer.
Medical subject headings
- Carcinoma, Transitional Cell
- Epirubicin
- Mitomycin
- Neoplasm Recurrence, Local
- Urinary Bladder Neoplasms